A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.
Also called NCT05662332
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 795 participants
- Sponsor
- Registry
-
NCT05662332
-
- Other papers using this trial's data
- Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT05662332. Randomized; no masking; primary purpose treatment. Start 2023-01-14 (actual); primary completion 2024-07-19 (actual). Results posted on 2025-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
- Acronym
- QWINT-1
- Condition
- Type 2 Diabetes
- Condition
- T2D
- Intervention (Drug)
- Insulin Efsitora Alfa
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05662332- Content hash
065ad84fb1cf66eef420842b6c2c0a20514351181d1744d90b4b94fa46e28948